DCOY Decoy Therapeutics, Inc.

NASDAQ
$2.69

Decoy Therapeutics, Inc. (DCOY) Institutional Ownership

What the institutions did with DCOY last quarter, from their 13F filings. Counting managers rather than shares is the point: a single index fund adding to a position tells you far less than four hundred separate managers all deciding to. Positions as reported for the quarter ended June 30, 2026.

Managers compared
6
filed both this quarter and last
Managers holding
4
+0 on the quarter
Buyers
2
2 opened new
Sellers
4
2 sold out entirely
Buyer share
33.3%
of managers who traded it
Breadth
-33.3
net buyers, as a share of those trading

Only 6 managers reported a position this quarter, so the percentages above describe a very small sample.

Every manager below opens. Subscribers can see any firm's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.

Sign in or subscribe

Ownership map

Each block is one manager, sized by shares held and colored by how much they moved the position last quarter. Green added, red cut, grey stood pat.

Cut Unchanged Added Color saturates at ±50%.

Largest holders

Manager Shares % of reported
VANGUARD CAPITAL MANAGEMENT LLC 4.0K 93.4%
Tower Research Capital LLC (TRC) 256 5.9%
UBS Group AG 25 0.6%
Caitong International Asset Management Co., Ltd 2 0.0%

Largest changes

Manager Action Previous Current Change
VANGUARD CAPITAL MANAGEMENT LLC New 0 4.0K +4.0K
Tower Research Capital LLC (TRC) Reduced 1.0K 256 -765
UBS Group AG Reduced 546 25 -521
Advisory Services Network, LLC Sold Out 41 0 -41
Caitong International Asset Management Co., Ltd New 0 2 +2
MORGAN STANLEY Sold Out 1 0 -1

13F filings are due 45 days after quarter end and cover long positions in U.S.-listed equities only, so this is a lagged and partial picture: shorts, bonds and foreign listings never appear. Options positions are excluded here rather than folded into the share counts. Political ownership is coming.